Sanofi gets 3 million-euro fine in Depakine caseTuesday’s Libération (p17) and Les Echos (p17) reported that a French court has fined Sanofi 3 million euros to compensate a victim of its epilepsy treatment Depakine (sodium valproate).
Launch of new haemophilia treatment blocked by reimbursement issuesWednesday’s Libération reported that an unnamed new treatment for type B haemophilia, approved in March 2016, has still not been approved for reimbursement by the French authorities, despite lobbying by France's biggest patients' association.
British pharma, chemicals industries brace for Brexit impactLes Echos (p16) on Thursday published an article on how the British chemical and pharmaceutical industries are bracing for the impact of Brexit, noting they were the first sectors to voice their concerns about the move.
Sanofi wants to 'bet on innovation' againThursday’s Les Echos (p19) and Le Figaro (p26) reported that Sanofi pledged to "return to an innovation-based strategy" after the company's recent focus on large-scale acquisitions.
Merck KGaA warns it will stop supplying old version of Levothyrox in March 2018Friday’s Le Parisien (p10) and Les Echos (brief p16) report that Merck KGaA has announced it will stop supplying the previous formulation of its thyroid disorder treatment Levothyrox (levothyroxine) after March 2018.
Teva reduces workforce by a quarterOn Friday, Les Echos (p21) reports on Teva's decision to reduce its workforce by 25%, or 14,000 jobs (APMHE 56052).
GPs increase antibiotics prescriptionsFriday’s Libération (brief p19) writes that French drugs agency ANSM has said prescriptions of antibiotics by GPs rose by 1.3% between 2015 and 2016.
Biotech seeks funds to develop cannabis addiction treatmentTuesday’s Les Echos (p23) reported that French biotech Aelis Farma is aiming to raise 30 million euros in order to finance the development of a treatment for cannabis addiction.
TRY APM HEALTH EUROPE AND GET ACCESS TO THE FULL CONTENT
Interviews with KOLs/senior executives amongst the Regulators, Payers, Health, Medical & Pharmaceutical organisations
Events coverage with a unique focus on Market Access & sustainability of healthcare systems
6 European bureaus : Berlin, Brussels, London, Madrid, Milan & Paris
Ask for a Free trial and get access to our last stories
- Health Care
- Market Access
- HTA – policies & practices
- European medicine regulations
- Drug safety issues
- Pricing & Reimbursement
- International medicines agencies
If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.
an initial 10 day temporary access of APM Health Europe.